Almirall, S.A. has acquired products from Allergan’s Dermatology unit in the U.S. for a cash consideration of $550M. The products include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (flurandrenolide), as well as sarecycline, a New Chemical Entity (NCE) currently under FDA review for the treatment of acne. These products expand Almirall’s presence in the U.S. through their subsidiary Aqua Pharmaceuticals, a manufacturer of established therapies for a...